People: AstraZeneca PLC (AZN.L)
Mr. Marc Dunoyer has been appointed as Chief Financial Officer, Executive Director of AstraZeneca PLC, effective 1 November 2013. He joined AstraZeneca from GlaxoSmithKline in June 2013. Marc qualified as an accountant. His subsequent career in pharmaceuticals has given him extensive experience of the industry including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganisation; and business development. A French national with a background in finance and accounting, Marc Dunoyer began his career in the pharmaceutical industry at Roussel Uclaf in Paris in the 1970s before being promoted to the position of President, Japan and then President, Asia Pacific. After returning to France for a period as Managing Director, Global Pharmaceuticals Division, Roussel Uclaf in the 1990s, Marc was appointed President & CEO, Asia Pacific & Japan for Hoechst Marion Roussel in 1995. In 2000, he was recruited by Glaxo Wellcome - just ahead of the merger that created GlaxoSmithKline - as Regional President, Japan and subsequently Regional President, Asia Pacific & Japan. His most recent role before joining AstraZeneca was Global Head of Rare Diseases and (concurrently) Chairman, GSK Japan for GlaxoSmithKline. Marc has an MBA from the Hautes Etudes Commerciales and has a Bachelor of Law degree from Paris University. He qualified as a Junior Certified Public Accountant in France.
|Total Annual Compensation, GBP||259,000|
|Restricted Stock Awards, GBP||--|
|Long-Term Incentive Plans, GBP||--|
|All Other, GBP||37,000|
|Fiscal Year Total, GBP||296,000|